Author

R. I. Corona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:differential expression· 2 Assay:whole-genome sequencing· 2

Frequent Co-Authors

K. Lawrenson· 5 shared J. Reddy· 3 shared J.-H. Seo· 3 shared M. L. Freedman· 3 shared S. A. Gayther· 3 shared A. Gusev· 2 shared B. Y. Karlan· 2 shared D. Chaves-Moreira· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

K. Lawrenson

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Rare germline genetic variation in PAX8 transcription factor binding sites and susceptibility to epithelial ovarian cancer

S. A. M. Ezquina, M. Jones, E. Dicks, A. de Vries, P.-C. Peng, R. I. Corona, K. Lawrenson, J. P. Tyrer, D. Hazelett, J. D. Brenton, A. C. Antoniou, S. A. Gayther, P. D. P. Pharoah

This study investigates rare germline variation in PAX8 binding sites for ovarian cancer risk using burden testing but finds no significant association.

medRxiv · Mar 22, 2023 · PreprintGenetic & Genomic Medicine

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

PAX8 orchestrates an angiogenic program through interaction with SOX17

D. Chaves-Moreira, M. A. Mitchell, C. Arruza, P. Rawat, S. Sidoli, R. Nameki, J. Reddy, R. I. Corona, S. Ma, B. Winterhoff, G. E. Konecny, B. A. Garcia, D. C. Brady, K. Lawrenson, P. J. Morin, R. Drapkin

This study identifies SOX17 as a PAX8-interacting partner and shows their role in regulating tumor angiogenesis in ovarian cancer, suggesting a new therapeutic target.

bioRxiv · Sep 9, 2020 · PreprintCancer Biology

Predicting master transcription factors from pan-cancer expression data

J. Reddy, M. A. S. Fonseca, R. I. Corona, R. Nameki, F. Segato Dezem, I. A. Klein, H. Chang, D. Chaves-Moreira, L. Afeyan, T. M. Malta, X. Lin, F. Abbasi, A. Font-Tello, T. Sabedot, P. Cejas, , K. Lawrenson

This paper introduces CaCTS, an algorithm that identifies candidate master transcription factors (MTFs) across 34 cancer types using RNA-seq data, revealing novel MTFs and functional groupings.

bioRxiv · Nov 12, 2019Cancer Biology

Non-coding Somatic Mutations Converge on the PAX8 Pathway in Epithelial Ovarian Cancer

R. I. Corona, J.-H. Seo, X. Lin, D. J. Hazelett, J. Reddy, F. Abassi, Y. G. Lin, P. Y. Mhawech-Fauceglia, J. Lester, S. P. Shah, D. G. Huntsman, A. Gusev, B. Y. Karlan, B. P. Berman, M. L. Freedman, , K. Lawrenson

The paper identifies histotype-specific regulatory elements in ovarian cancer by integrating chromatin landscapes and somatic mutations, highlighting the PAX8 pathway's role in tumor development.

bioRxiv · Feb 1, 2019Cancer Biology